View Post

Breast Cancer Drugs May Severely Inflame Lungs, FDA Warns

In In The News by Barbara Jacoby

From: Nick Mulcahy From: The US Food and Drug Administration (FDA) issued a warning today that the commonly prescribed breast cancer therapies known as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors may cause rare but severe inflammation of the lungs. The related products include palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Eli Lilly), which are approved for use …